Year: 2020
Type: article
Abstract: Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 weeks of peginterferon–ribavirin treatment for a sustained virologic response. We designed a noninferiority trial (noninferiority margin, −10.5%) to compare rates of sustained virologic response among patients receiving two treatment durations.
DOI: 10.17615/cjmt-0q40
Authors: Everson, Gregory T., Fried, Michael W., Afdhal, Nezam H., Nelson, David R., Adda, Nathalie, George, Shelley, Poordad, Fred, Reesink, Hendrik W., Sherman, Kenneth E., Kauffman, Robert S., Sulkowski, Mark S., Martin, Marie, Sankoh, Abdul J., Flamm, Steven L., Adler, Michael, Wright, Christopher I.
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Vertex Pharmaceuticals
OpenAlex ID: W4299540542